Место издания:USG-United Scientific Group # 8105, Rasor Blvd - Suite #112, PLANO, TX 75024, USA
Первая страница:32
Последняя страница:32
Аннотация:https://neurodiseases.unitedscientificgroup.org/pdfs/NVND_2021-Abstract-Book.pdf...Impulsive-compulsive and related behavioral disorders (ICD) are drug-induced non-motor behavioral complications in Parkinson’s disease (PD). Since dopaminergic and specifically dopamine agonists therapy is considered the main risk factor for ICD development, a large body of work has focused on pharmacogenetic approaches for prediction and management of ICD in PD. The aim of our study was to evaluate the role of candidate genes such asDBH, DRD2, MAOA, BDNF, COMT, SLC6A4, SLC6A3, ACE, DRD1 polymorphismsand links to pathogenesis of ICD in PD. We compared patients with PD and ICD (n=49), patients with PD without ICD (n=36) and a population control group (n=365). ICD was diagnosed using the QUIP questionnaires and a specific diagnostic criteria for ICD subtypes. Genotyping was conducted using PCR, Real-Time PCR, SNaPshot, and PCR-RFLP techniques. Statistical analysis was performed using WinPepi and APSampler v3.6 software. PCA testing was conducted using RStudio software. The following substitutions showed statistically significant correlations with PD and ICD: DBH (rs2097629, rs1611115), DRD2 (rs6275, rs12364283, rs1076560), ACE (rs4646994), DRD1 (rs686), BDNF (rs6265); and these are novel associations in Russian PD patients. Our findings suggest that polymorphisms in DBH, BDNF, DRD2, ACE genes are associated with an increased risk of ICD development in Russian PD patients. Of specific interest is rs6275 DRD2 gene polymorphism which is associated with a strong clinical genetic risk factor for the development of ICD in PD patients and may therefore enable pharmacogenetic strategies to aid personalized treatment and prophylaxis.